Please login to the form below

Not currently logged in
Email:
Password:

Dr Sunita Zalani joins Intarcia Therapeutics as regulatory head

Moves to the Boston company from Onyx Pharmaceuticals
Intarcia Therapeutics Sunita Zalani

Boston-based biopharmaceutical firm Intarcia Therapeutics has appointed Dr Sunita Zalani as vice president, global head of regulatory affairs and quality.

She joins the company from Amgen's Onyx Pharmaceuticals subsiary, where she served as vice president of global regulatory affairs.

Dr Zalani had been with Onyx - which was acquired by Amgen last year - since 2004 and prior to that worked at Lilly as its global regulatory lead.

In her new role at Inarcia, whose most advanced prospect is a phase III version of the diabetes drug exenatide that only needs to be given once a year, Dr Zalani will sit on the leadership team and report directly to chairman, president and CEO Kurt Graves.

He said: "We led a very competitive search for the person who would best meet the steep demands of our global regulatory and quality functions, and I'm delighted Intarcia prevailed as Sunita's choice out of several other simultaneous options she had.

“Her track record shows her to be a team leader with a 'gut grasp' of how to succeed in the biotech industry.”

6th August 2014

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Langland

Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...